Quarterly report [Sections 13 or 15(d)]

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

v3.25.3
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 3 Months Ended
Sep. 30, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

 

Derivative Financial Instruments:

 

The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity, under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, warrants and embedded conversion options in convertible debt are recorded as a liability and are revalued at fair value at each reporting date. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date. The Company had $131,000 (3 notes) and $291,650 (9 notes) of convertible debt, which were treated as derivative instruments outstanding at September 30, 2025 and June 30, 2025, respectively.

 

The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at September 30, 2025, the last trading day of the period ended September 30, 2025, was $1.70. The volatility, expected remaining term and risk-free interest rates used to estimate the fair value of derivative liabilities at September 30, 2025 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk-free rate is based upon rates for treasury securities with the same term.

 

Convertible Debt

 

   

Initial Valuations
(on new derivative
instruments entered
into during the three
months ended
September 30, 2025)

     September 30, 2025  
Volatility     -       425 %
Expected Remaining Term (in years)     -       0.02 - 0.70  
Risk Free Interest Rate     -       3.98-4.20 %
Expected dividend yield     None       None  

 

Fair Value Measurements:

 

The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis As of September 30, 2025 and June 30, 2025:

 

    Balance at
September 30,
2025		     Quoted Prices
in Active
Markets for
Identical
Assets		     Significant
Other
Observable
Inputs		     Significant
Unobservable Inputs		  
          (Level 1)     (Level 2)     (Level 3)  
Embedded conversion option liabilities   $ 167,878     $ —     $ —     $ 167,878  
Total   $ 167,878     $ —     $ —     $ 167,878  

 

    Balance at
June 30, 2025		    

Quoted Prices
in Active
Markets for
Identical
Assets

    

Significant
Other
Observable
Inputs

    

Significant
Unobservable Inputs

  
          (Level 1)     (Level 2)     (Level 3)  
Embedded conversion option liabilities   $ 403,892     $ —     $ —     $ 403,892  
Total   $ 403,892     $ —     $ —     $ 403,892  

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

(Unaudited)

 

The following is a roll forward for the three months ended September 30, 2025 of the fair value liability of price adjustable derivative instruments:

 

 

    Fair Value of  
    Liability for  
    Derivative  
    Instruments  
Balance at June 30, 2025   $ 403,892  
Gain on debt extinguishment     (255,720 )
Change in fair value included in statements of operations     19,706  
Balance at September 30, 2025   $ 167,878